The predictive potential of hyponatremia for glioblastoma patient survival

Oliver D. Mrowczynski, Alexandre J. Bourcier, Jiangang (Jason) Liao, Sara T. Langan, Charles Specht, Elias Rizk

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Glioblastoma is a devastating malignancy with a dismal survival rate. Currently, there are limited prognostic markers of glioblastoma including IDH1, ATRX, MGMT, PTEN, EGFRvIII, and others. Although these biomarkers for tumor prognosis are available, a surgical biopsy must be performed for these analyses, which has morbidity involved. A non-invasive and readily available biomarker is sought after which provides clinicians prognostic information. Sodium is an electrolyte that is easily and quickly obtained through analysis of a patient’s serum. Hyponatremia has been shown to have a predictive and negative prognostic indication in multiple cancer types, but the role of glioblastoma patients’ serum sodium at the time of diagnosis in predicting glioblastoma patient survival has not been determined. We assessed whether hyponatremia at the time of glioblastoma diagnosis correlates to patient survival and show that in our cohort of 200 glioblastoma patients, sodium, at any level, did not significantly correlate to glioblastoma survival, unlike what is seen in multiple other cancer types. We further demonstrate that inducing hyponatremia in an orthotopic murine model of glioblastoma has no effects on tumor progression and survival.

Original languageEnglish (US)
Pages (from-to)99-104
Number of pages6
JournalJournal of neuro-oncology
Volume138
Issue number1
DOIs
StatePublished - May 1 2018

Fingerprint

Hyponatremia
Glioblastoma
Survival
Sodium
Neoplasms
Tumor Biomarkers
Serum
Electrolytes
Survival Rate
Biomarkers
Morbidity
Biopsy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Mrowczynski, Oliver D. ; Bourcier, Alexandre J. ; Liao, Jiangang (Jason) ; Langan, Sara T. ; Specht, Charles ; Rizk, Elias. / The predictive potential of hyponatremia for glioblastoma patient survival. In: Journal of neuro-oncology. 2018 ; Vol. 138, No. 1. pp. 99-104.
@article{8635520441804a469dc249802198ecb7,
title = "The predictive potential of hyponatremia for glioblastoma patient survival",
abstract = "Glioblastoma is a devastating malignancy with a dismal survival rate. Currently, there are limited prognostic markers of glioblastoma including IDH1, ATRX, MGMT, PTEN, EGFRvIII, and others. Although these biomarkers for tumor prognosis are available, a surgical biopsy must be performed for these analyses, which has morbidity involved. A non-invasive and readily available biomarker is sought after which provides clinicians prognostic information. Sodium is an electrolyte that is easily and quickly obtained through analysis of a patient’s serum. Hyponatremia has been shown to have a predictive and negative prognostic indication in multiple cancer types, but the role of glioblastoma patients’ serum sodium at the time of diagnosis in predicting glioblastoma patient survival has not been determined. We assessed whether hyponatremia at the time of glioblastoma diagnosis correlates to patient survival and show that in our cohort of 200 glioblastoma patients, sodium, at any level, did not significantly correlate to glioblastoma survival, unlike what is seen in multiple other cancer types. We further demonstrate that inducing hyponatremia in an orthotopic murine model of glioblastoma has no effects on tumor progression and survival.",
author = "Mrowczynski, {Oliver D.} and Bourcier, {Alexandre J.} and Liao, {Jiangang (Jason)} and Langan, {Sara T.} and Charles Specht and Elias Rizk",
year = "2018",
month = "5",
day = "1",
doi = "10.1007/s11060-018-2774-z",
language = "English (US)",
volume = "138",
pages = "99--104",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

The predictive potential of hyponatremia for glioblastoma patient survival. / Mrowczynski, Oliver D.; Bourcier, Alexandre J.; Liao, Jiangang (Jason); Langan, Sara T.; Specht, Charles; Rizk, Elias.

In: Journal of neuro-oncology, Vol. 138, No. 1, 01.05.2018, p. 99-104.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The predictive potential of hyponatremia for glioblastoma patient survival

AU - Mrowczynski, Oliver D.

AU - Bourcier, Alexandre J.

AU - Liao, Jiangang (Jason)

AU - Langan, Sara T.

AU - Specht, Charles

AU - Rizk, Elias

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Glioblastoma is a devastating malignancy with a dismal survival rate. Currently, there are limited prognostic markers of glioblastoma including IDH1, ATRX, MGMT, PTEN, EGFRvIII, and others. Although these biomarkers for tumor prognosis are available, a surgical biopsy must be performed for these analyses, which has morbidity involved. A non-invasive and readily available biomarker is sought after which provides clinicians prognostic information. Sodium is an electrolyte that is easily and quickly obtained through analysis of a patient’s serum. Hyponatremia has been shown to have a predictive and negative prognostic indication in multiple cancer types, but the role of glioblastoma patients’ serum sodium at the time of diagnosis in predicting glioblastoma patient survival has not been determined. We assessed whether hyponatremia at the time of glioblastoma diagnosis correlates to patient survival and show that in our cohort of 200 glioblastoma patients, sodium, at any level, did not significantly correlate to glioblastoma survival, unlike what is seen in multiple other cancer types. We further demonstrate that inducing hyponatremia in an orthotopic murine model of glioblastoma has no effects on tumor progression and survival.

AB - Glioblastoma is a devastating malignancy with a dismal survival rate. Currently, there are limited prognostic markers of glioblastoma including IDH1, ATRX, MGMT, PTEN, EGFRvIII, and others. Although these biomarkers for tumor prognosis are available, a surgical biopsy must be performed for these analyses, which has morbidity involved. A non-invasive and readily available biomarker is sought after which provides clinicians prognostic information. Sodium is an electrolyte that is easily and quickly obtained through analysis of a patient’s serum. Hyponatremia has been shown to have a predictive and negative prognostic indication in multiple cancer types, but the role of glioblastoma patients’ serum sodium at the time of diagnosis in predicting glioblastoma patient survival has not been determined. We assessed whether hyponatremia at the time of glioblastoma diagnosis correlates to patient survival and show that in our cohort of 200 glioblastoma patients, sodium, at any level, did not significantly correlate to glioblastoma survival, unlike what is seen in multiple other cancer types. We further demonstrate that inducing hyponatremia in an orthotopic murine model of glioblastoma has no effects on tumor progression and survival.

UR - http://www.scopus.com/inward/record.url?scp=85040904196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040904196&partnerID=8YFLogxK

U2 - 10.1007/s11060-018-2774-z

DO - 10.1007/s11060-018-2774-z

M3 - Article

C2 - 29372493

AN - SCOPUS:85040904196

VL - 138

SP - 99

EP - 104

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -